



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Methyldopa

<b>Cat. No.:</b>	HY-B0225		
<b>CAS No.:</b>	555-30-6		
<b>Molecular Formula:</b>	C <sub>10</sub> H <sub>13</sub> NO <sub>4</sub>		
<b>Molecular Weight:</b>	211.21		
<b>Target:</b>	Adrenergic Receptor; Endogenous Metabolite		
<b>Pathway:</b>	GPCR/G Protein; Neuronal Signaling; Metabolic Enzyme/Protease		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### BIOLOGICAL ACTIVITY

<b>Description</b>	Methyldopa (L-(-)-α-Methyldopa), a potent antihypertensive agent, is an alpha-adrenergic agonist (selective for α <sub>2</sub> -adrenergic receptors). Methyldopa is a proagent and is metabolized (α-Methylepinephrine) in the central nervous system <sup>[1]</sup> [2].								
<b>IC<sub>50</sub> &amp; Target</b>	α adrenergic receptor								
<b>In Vivo</b>	<p>Methyldopa (L-(-)-α-Methyldopa; 200 mg/kg; i.p.) decreases the hyperglycemic response in the first 2 hr after Dieldrin treatment<sup>[2]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>60-day-old male rats<sup>[2]</sup></td> </tr> <tr> <td>Dosage:</td> <td>200 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>i.p.</td> </tr> <tr> <td>Result:</td> <td>Decreased the plasma concentration of glucose in Dieldrin-exposed rats by 24% during the 30 min following its administration.</td> </tr> </table>	Animal Model:	60-day-old male rats <sup>[2]</sup>	Dosage:	200 mg/kg	Administration:	i.p.	Result:	Decreased the plasma concentration of glucose in Dieldrin-exposed rats by 24% during the 30 min following its administration.
Animal Model:	60-day-old male rats <sup>[2]</sup>								
Dosage:	200 mg/kg								
Administration:	i.p.								
Result:	Decreased the plasma concentration of glucose in Dieldrin-exposed rats by 24% during the 30 min following its administration.								

### CUSTOMER VALIDATION

- Clin Chem. 2019 Dec;65(12):1522-1531.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

### REFERENCES

[1]. Sweet CS. New centrally acting antihypertensive drugs related to methyldopa and clonidine. Hypertension. 1984;6(5 Pt 2):II51-II56.

---

[2]. Fox GR, et al. The effects of phenobarbital, atropine, L-alpha-methyldopa, and DL-propranolol on dieldrin-induced hyperglycemia in the adult rat. Toxicol Appl Pharmacol. 1985;78(3):342-350.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA